Evommune shares fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year.
June 29, 2026 10:45 AM EDT
Evommune's lead drug fails in chronic hives, stock sinks
Max Gelman
Evommune’s shares $EVMN fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year.
In …
Evommune's Skin Disorder Study Falls Short - Evommune (NYSE:EVMN)
Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Omeros (NASDAQ:OMER)
After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL
Abivax rallies 36% as trial data ease safety fears over obefazimod
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Abivax seeks to ease safety concerns with new data, boosting shares
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
What's Going On With Biohaven Stock Monday? - Biohaven (NYSE:BHVN)
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Toast (NYSE:TO
